CR7869A - Agonistas morfolinicos de la dopamina - Google Patents
Agonistas morfolinicos de la dopaminaInfo
- Publication number
- CR7869A CR7869A CR7869A CR7869A CR7869A CR 7869 A CR7869 A CR 7869A CR 7869 A CR7869 A CR 7869A CR 7869 A CR7869 A CR 7869A CR 7869 A CR7869 A CR 7869A
- Authority
- CR
- Costa Rica
- Prior art keywords
- morpholinic
- dopamine
- agonists
- alkyl
- conh2
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 239000000556 agonist Substances 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion proporciona compuestos de las formulas (I), (Ia) y (Ib) en las que A se selecciona entre C-X y N, B se selecciona entre C- Y y N, R1 se selecciona entre H y alquilo C1-C6, R2 se selecciona entre H y alquilo C1-C6, X se selecciona entre H, HO, C (O) NH2, NH2, Y se selecciona entre H, HO, NH2, Br, CI y F, Z se selecciona entre H, HO, F, CONH2 y CN; y sus sales, solvatos y profarmacos farmaceuticamente aceptables.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0228787A GB0228787D0 (en) | 2002-12-10 | 2002-12-10 | Morpholine dopamine agonists |
| GB0308460A GB0308460D0 (en) | 2003-04-11 | 2003-04-11 | Morpholine dopamine agonists |
| GB0313606A GB0313606D0 (en) | 2003-06-12 | 2003-06-12 | Morpholine dopamine agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7869A true CR7869A (es) | 2005-07-08 |
Family
ID=32512061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7869A CR7869A (es) | 2002-12-10 | 2005-06-10 | Agonistas morfolinicos de la dopamina |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1572214B1 (es) |
| JP (3) | JP3889775B2 (es) |
| KR (1) | KR100796102B1 (es) |
| AP (1) | AP2005003325A0 (es) |
| AR (1) | AR042339A1 (es) |
| AT (1) | ATE460938T1 (es) |
| AU (1) | AU2003302878B2 (es) |
| CA (1) | CA2508262C (es) |
| CO (1) | CO5700781A2 (es) |
| CR (1) | CR7869A (es) |
| CY (1) | CY1110130T1 (es) |
| DE (1) | DE60331769D1 (es) |
| DK (1) | DK1572214T3 (es) |
| EA (1) | EA009589B1 (es) |
| EC (1) | ECSP055850A (es) |
| ES (1) | ES2339767T3 (es) |
| GE (1) | GEP20074272B (es) |
| HN (1) | HN2003000401A (es) |
| HR (1) | HRP20050523A2 (es) |
| IS (1) | IS7843A (es) |
| MA (1) | MA27605A1 (es) |
| MX (1) | MXPA05006151A (es) |
| MY (1) | MY144338A (es) |
| NL (1) | NL1024983C2 (es) |
| NO (1) | NO330143B1 (es) |
| NZ (1) | NZ540505A (es) |
| OA (1) | OA13014A (es) |
| PA (1) | PA8591601A1 (es) |
| PE (1) | PE20040906A1 (es) |
| PL (1) | PL377480A1 (es) |
| PT (1) | PT1572214E (es) |
| RS (1) | RS51442B (es) |
| SI (1) | SI1572214T1 (es) |
| TW (1) | TW200423944A (es) |
| UY (1) | UY28117A1 (es) |
| WO (1) | WO2004052372A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE404560T1 (de) * | 2004-05-26 | 2008-08-15 | Pfizer | Indazol- und indolonderivative und deren verwendung als pharmazeutika |
| JP4198183B2 (ja) * | 2004-05-27 | 2008-12-17 | ファイザー・インク | 選択的ドーパミンｄ３アゴニストとしてのアミノピリジン誘導体 |
| GB0502509D0 (en) | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| GB0700786D0 (en) * | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| AU2011255456B2 (en) | 2010-05-21 | 2017-01-19 | Dignity Health Doing Business As St. Joseph's Hospital And Medical Center And Barrow Neurological Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| EP2571858B1 (en) * | 2010-05-21 | 2018-06-20 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| RU2677328C1 (ru) * | 2013-12-11 | 2019-01-16 | Ф. Хоффманн-Ля Рош Аг | Способ получения хиральных 2-арилморфолинов |
| GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| EP3725768A1 (en) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
| CN118684636B (zh) * | 2024-05-31 | 2025-03-11 | 上海优合贝德医药科技有限公司 | 一种4-吗啉-1-苯基巯基-2-丁酮的合成工艺 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
| GB9108629D0 (en) * | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
-
2003
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 EP EP03812639A patent/EP1572214B1/en not_active Expired - Lifetime
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active Expired - Fee Related
- 2003-12-02 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
-
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
-
2006
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528797T3 (es) | Compuestos de aza-benzotiofenilo y métodos de uso | |
| CR7865A (es) | Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1) | |
| CR9614A (es) | Inhibidores heterobiciclicos de las metaloproteasas | |
| CR7869A (es) | Agonistas morfolinicos de la dopamina | |
| HN2003000408A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| AR047823A1 (es) | Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida | |
| ES2193990T3 (es) | Derivados de purina. | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| PA8518801A1 (es) | Derivados de 2-aminocarbonil-9h-purina | |
| UY30048A1 (es) | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| CR7684A (es) | Derivados de heterobiarilo como inhibidores de metaloproteinas de la matriz | |
| NI200800306A (es) | Polimorfos de n-hidroxi - 3 - [4 - [[[2 - (2-metil - 1h - indol - 3 - il) etil] amino] metil] fenil] - 2e - 2 - propenamida. | |
| EA200970372A1 (ru) | Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение | |
| CO5580821A2 (es) | 4-cetolactamas y -lactonas 3-fenil-3-substituidas, espirociclicas | |
| RS53063B (en) | MGLU2 AGONISTS | |
| AR041340A1 (es) | Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen | |
| UY27236A1 (es) | Inhibidores de pcp basados en ácidos 3-heterociclilpropanohidroxámicos | |
| PE20040669A1 (es) | Derivados de fenilalanina enamida | |
| SV2004001370A (es) | Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones | |
| AR053989A1 (es) | Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas y procesos de obtencion. | |
| UY28089A1 (es) | Compuestos calciliticos | |
| GT200000090A (es) | Nuevos derivados de equinocandina, su procedimiento de preparacion y su aplicacion como antifungicos. | |
| ES2190781T3 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano. | |
| UY27741A1 (es) | Supositorios de meloxicam | |
| DOP2003000764A (es) | Agonistas morfolinicos de la dopamina |